companies developing glp-1 drugs Anti-Obesity – Pharma Race to Grab a Bite of the Pie Inside the GLP-1 Boom: What

LEADER (liraglutide) [44], SUSTAIN-6 (semaglutide) [67], and REWIND (dulaglutide) [70] study showed beneficial renal outcomes, mainly reducing the occurrence of proteinuria

Functional and Clinical Relevance of Novel and Known PCSK1 Variants for Childhood Obesity and Glucose Metabolism. Molecular Metabolism, vol

Food and Drug Administration (FDA) in 2011

doi: 10.1016/S0140-6736(19)33041-7

If we never address how we gained weight to begin with, those root causes get transferred to something else - in this case increased anxiety, depression, agitation, listlessness and more

One of the most exciting future directions for GLP-1-mediated therapeutic interventions is personalized diabetes care